Optimizerx Corporation (OPRX)
NASDAQ (CM) NASDAQ (CM) Primary 
OptimizeRx: How The Stock Is Changing Pharma Marketing
OptimizeRx Corporation is evolving from an EHR messaging platform to a clinical data and AI-driven advertising company, leveraging DAAP and MNT technologies. Q2 2025 financials show strong revenue growth, improved margins, and a shift to higher-margin subscription revenues, supporting management's raised guidance for 2025. The Lamar partnership and expanding mid-tier pharma client base diversify revenue streams, reduce risk, and confirm OPRX's strategic pivot to broader advertising markets.
OptimizeRx Bets on AI and Workflow Integration - Will This Pay Off?
OPRX posts 55% revenue growth and raises outlook as AI-driven workflow integration fuels leverage and pharma adoption.
All You Need to Know About OptimizeRx (OPRX) Rating Upgrade to Strong Buy
OptimizeRx (OPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
OptimizeRx Corporation (OPRX) Q2 2025 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrew Jacob D'Silva - Senior Vice President of Corporate Finance Edward Stelmakh - CFO & COO Stephen L. Silvestro - President & CEO Conference Call Participants Anderson Schock - B.
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.
Bull Of The Day: OptimizeRX (OPRX)
This stock is reporting earnings next week and posting positive operating margins is going to be key.
Does OptimizeRx Have a Moat in the Crowded HealthTech Space?
OptimizeRx OPRX is carving out a secure niche in the increasingly crowded HealthTech landscape, signaling a developing moat anchored in scale, data and execution. Over the previous two quarters, the company has posted double-digit top-line growth.
OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?
OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.
OptimizeRx: Stock Could Rise As Profitability Is Achieved
I expect OptimizeRx to turn profitable in 2025, driven by strong double-digit revenue growth and reduced operating expenses. The company's proprietary AI-powered omnichannel platform connects over 2 million healthcare providers with millions of patients, enabling effective targeted marketing. OPRX's unique Dynamic Audience Activation Platform and Micro-Neighborhood Targeting differentiate it from competitors and support its patient-centered strategy.
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
OptimizeRx bets on EHR-linked messaging and geo-targeting to stand out, but scaling in a crowded digital health field remains key.
OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?
OPRX is growing faster with rising subscription revenues and strong pharma demand, while GDRX lags due to slower consumer growth.
OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?
OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.
